Estrogen Induces RAD51C Expression and Localization to Sites of DNA Damage

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2016 Nov 5

PMID 27753535

Citations 7

Authors

Anya Alayev

Rachel S Salamon

Subrata Manna

Naomi S Schwartz

Adi Y Berman

Marina K Holz

Affiliations

Soon will be listed here.

Abstract

Homologous recombination (HR) is a conserved process that maintains genome stability and cell survival by repairing DNA double-strand breaks (DSBs). The RAD51-related family of proteins is involved in repair of DSBs; consequently, deregulation of RAD51 causes chromosomal rearrangements and stimulates tumorigenesis. RAD51C has been identified as a potential tumor suppressor and a breast and ovarian cancer susceptibility gene. Recent studies have also implicated estrogen as a DNA-damaging agent that causes DSBs. We found that in ERα-positive breast cancer cells, estrogen transcriptionally regulates RAD51C expression in ERα-dependent mechanism. Moreover, estrogen induces RAD51C assembly into nuclear foci at DSBs, which is a precursor to RAD51 complex recruitment to the nucleus. Additionally, disruption of ERα signaling by either anti-estrogens or siRNA prevented estrogen induced upregulation of RAD51C. We have also found an association of a worse clinical outcome between RAD51C expression and ERα status of tumors. These findings provide insight into the mechanism of genomic instability in ERα-positive breast cancer and suggest that individuals with mutations in RAD51C that are exposed to estrogen would be more susceptible to accumulation of DNA damage, leading to cancer progression.

Citing Articles

Genome-wide mapping and quantification of DNA damage induced by catechol estrogens using Click-Probe-Seq and LC-MS.

Do Q, Tzeng S, Wang C, Wu C, Kafeenah H, Chen S Commun Biol. 2025; 8(1):357.

PMID: 40069327 PMC: 11897211. DOI: 10.1038/s42003-025-07657-0.

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.

Lazzari G, Opattova A, Arena S J Exp Clin Cancer Res. 2024; 43(1):146.

PMID: 38750579 PMC: 11094891. DOI: 10.1186/s13046-024-03065-0.

Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway.

Abe A, Imoto I, Ueki A, Nomura H, Kanao H Int J Mol Sci. 2022; 23(19).

PMID: 36233090 PMC: 9570179. DOI: 10.3390/ijms231911790.

The Interplay between the Cellular Response to DNA Double-Strand Breaks and Estrogen.

Yedidia-Aryeh L, Goldberg M Cells. 2022; 11(19).

PMID: 36231059 PMC: 9563627. DOI: 10.3390/cells11193097.

Fanconi anemia and mTOR pathways functionally interact during stalled replication fork recovery.

Nolan M, Knudson K, Holz M, Chaudhury I FEBS Lett. 2021; 595(5):595-603.

PMID: 33423298 PMC: 7993987. DOI: 10.1002/1873-3468.14035.

References

Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V . Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010; 42(5):406-9. DOI: 10.1038/ng.570. View

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D . Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42(5):410-4. DOI: 10.1038/ng.569. View

Pittman D, Weinberg L, Schimenti J . Identification, characterization, and genetic mapping of Rad51d, a new mouse and human RAD51/RecA-related gene. Genomics. 1998; 49(1):103-11. DOI: 10.1006/geno.1998.5226. View

Min A, Im S, Yoon Y, Song S, Nam H, Hur H . RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013; 12(6):865-77. DOI: 10.1158/1535-7163.MCT-12-0950. View

Yamnik R, Digilova A, Davis D, Brodt Z, Murphy C, Holz M . S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2008; 284(10):6361-9. DOI: 10.1074/jbc.M807532200. View

Lin Z, Kong H, Nei M, Ma H . Origins and evolution of the recA/RAD51 gene family: evidence for ancient gene duplication and endosymbiotic gene transfer. Proc Natl Acad Sci U S A. 2006; 103(27):10328-10333. PMC: 1502457. DOI: 10.1073/pnas.0604232103. View

Badie S, Liao C, Thanasoula M, Barber P, Hill M, Tarsounas M . RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J Cell Biol. 2009; 185(4):587-600. PMC: 2711581. DOI: 10.1083/jcb.200811079. View

Venkitaraman A . Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108(2):171-82. DOI: 10.1016/s0092-8674(02)00615-3. View

Sharan S, Morimatsu M, Albrecht U, Lim D, Regel E, Dinh C . Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997; 386(6627):804-10. DOI: 10.1038/386804a0. View

10.

Gudmundsdottir K, Ashworth A . The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006; 25(43):5864-74. DOI: 10.1038/sj.onc.1209874. View

11.

Kuznetsov S, Haines D, Martin B, Sharan S . Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res. 2009; 69(3):863-72. PMC: 2754281. DOI: 10.1158/0008-5472.CAN-08-3057. View

12.

Williamson L, Lees-Miller S . Estrogen receptor α-mediated transcription induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis. 2010; 32(3):279-85. DOI: 10.1093/carcin/bgq255. View

13.

Gruver A, Miller K, Rajesh C, Smiraldo P, Kaliyaperumal S, Balder R . The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C. Mutagenesis. 2005; 20(6):433-40. DOI: 10.1093/mutage/gei059. View

14.

Bennett B, Knight K . Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51. J Cell Biochem. 2005; 96(6):1095-109. DOI: 10.1002/jcb.20640. View

15.

Wiegmans A, Miranda M, Wen S, Al-Ejeh F, Moller A . RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget. 2016; 7(37):60087-60100. PMC: 5312370. DOI: 10.18632/oncotarget.11065. View

16.

Antoni L, Sodha N, Collins I, Garrett M . CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat Rev Cancer. 2007; 7(12):925-36. DOI: 10.1038/nrc2251. View

17.

Jordan V . The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2014; 22(1):R1-31. PMC: 4494663. DOI: 10.1530/ERC-14-0448. View

18.

Tumiati M, Munne P, Edgren H, Eldfors S, Hemmes A, Kuznetsov S . Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers. Oncogene. 2016; 35(35):4601-10. DOI: 10.1038/onc.2015.528. View

19.

Ogawa T, Yu X, Shinohara A, Egelman E . Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science. 1993; 259(5103):1896-9. DOI: 10.1126/science.8456314. View

20.

Godthelp B, Wiegant W, van Duijn-Goedhart A, Scharer O, van Buul P, Kanaar R . Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res. 2002; 30(10):2172-82. PMC: 115287. DOI: 10.1093/nar/30.10.2172. View